MarketCap
Facebook
X
Telegram
Phreesia Balance Sheet 2026-2011 | PHR
Brief overview of Phreesia's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2022 and 2026.
Assets added +34.2%, reaching $663.8 million from $494.5 million five periods earlier; annual growth near 7.6% remained solid.
Liabilities grew faster than assets: +323.1% versus +34.2%. A substantial part of expansion was externally funded.
Internal capital represents 50.8% of the balance sheet, previously 84.4%. This is a strong capital position.
Negative net debt of -$69.9 million means cash holdings are larger than debt obligations.
Cash accounts for 11.1% of assets versus 63.5% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$799.2 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Phreesia's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Phreesia
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-69.9 M | -81.3 M | -84 M | -176 M | -312 M | -211 M | -66.5 M | 26.5 M | 10.1 M | - | - | - | - | - | - | - |
Long Term Debt |
2.66 M | 1.94 M | 3.15 M | 246 K | 360 K | 6.47 M | 19.4 M | 27.9 M | 19.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
1.25 M | 964 K | 393 K | 934 K | 1.28 M | 1.09 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 21.5 M | 242 M | 200 M | - | - | - | - | - | - | - |
Total Current Liabilities |
183 M | 114 M | 110 M | 79 M | 68.4 M | 55 M | 35.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
327 M | 124 M | 119 M | 82.2 M | 77.2 M | 63.4 M | 56.9 M | 270 M | 225 M | - | - | - | - | - | - | - |
Deferred Revenue |
49.5 M | 32.8 M | 24.1 M | 17.7 M | 16.5 M | 10.8 M | 5.4 M | 6.49 M | 4.89 M | - | - | - | - | - | - | - |
Retained Earnings |
-799 M | -801 M | -743 M | -606 M | -430 M | -312 M | -284 M | -211 M | -168 M | - | - | - | - | - | - | - |
Total Assets |
664 M | 388 M | 370 M | 370 M | 494 M | 327 M | 159 M | 59.3 M | 57.1 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
73.8 M | 84.2 M | 87.5 M | 177 M | 314 M | 219 M | 90.3 M | 1.54 M | 10.5 M | - | - | - | - | - | - | - |
Book Value |
337 M | 265 M | 251 M | 288 M | 417 M | 263 M | 102 M | -211 M | -168 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
337 M | 265 M | 251 M | 288 M | 417 M | 263 M | 102 M | -211 M | -168 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Phreesia
| 2027-Q1 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
612 K | 964 K | 1.3 M | 1.63 M | 2.32 M | 1.3 M | 1.63 M | 2.32 M | - | 2.88 M | 3.66 M | 3.88 M | 309 K | 2.72 M | 183 K | 158 K | 544 K | 1.63 M | 504 K | 469 K | 781 K | 19.4 M | 22.9 M | 23.5 M | 19.5 M | 27.9 M | 19.4 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
307 M | 103 M | 111 M | 118 M | 121 M | 111 M | 118 M | 121 M | - | 119 M | 110 M | 93.4 M | 90.2 M | 82.2 M | 76.9 M | 77.5 M | 77.9 M | 63.4 M | 71.2 M | 64.7 M | 57.9 M | 56.9 M | 68.4 M | 62.6 M | 61.4 M | 63.7 M | 53.4 M | 60.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
39.6 M | 29.7 M | 26.9 M | 31.1 M | 22.2 M | 26.9 M | 31.1 M | 22.2 M | - | 24.1 M | 22 M | 16.4 M | 17.9 M | 17.7 M | 13.9 M | 17.2 M | 17.8 M | 10.8 M | 12.4 M | 12.9 M | 13.2 M | 5.4 M | 6.62 M | 6.26 M | 6.63 M | 6.49 M | 5.33 M | 5.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-796 M | -800 M | -805 M | -805 M | -795 M | -805 M | -805 M | -795 M | - | -763 M | -712 M | -680 M | -644 M | -606 M | -568 M | -528 M | -481 M | -312 M | -383 M | -347 M | -323 M | -284 M | -304 M | -297 M | -291 M | -211 M | -281 M | -278 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
666 M | 423 M | 409 M | 400 M | 376 M | 409 M | 400 M | 376 M | - | 372 M | 375 M | 340 M | 354 M | 370 M | 397 M | 426 M | 459 M | 327 M | 529 M | 551 M | 561 M | 159 M | 338 M | 160 M | 161 M | 59.3 M | 156 M | 163 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
76.4 M | 106 M | 98.3 M | 90.9 M | 81.7 M | 98.3 M | 90.9 M | 81.7 M | 81.8 M | 79.5 M | 103 M | 128 M | 150 M | 177 M | 210 M | 241 M | 269 M | 219 M | 400 M | 440 M | 451 M | 90.3 M | 254 M | 84.2 M | 90.3 M | 1.54 M | 91.4 M | 100 M | 5.91 M | 10.5 M | 2.61 M | 4.43 M | - | 2.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
359 M | 320 M | 298 M | 282 M | 255 M | 298 M | 282 M | 255 M | - | 253 M | 265 M | 247 M | 264 M | 288 M | 320 M | 348 M | 381 M | 263 M | 458 M | 487 M | 503 M | 102 M | 270 M | 97.7 M | 99.9 M | -4.48 M | 102 M | 103 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
359 M | 320 M | 298 M | 282 M | 255 M | 298 M | 282 M | 255 M | 251 M | 253 M | 265 M | 247 M | 264 M | 288 M | 320 M | 348 M | 381 M | 263 M | 458 M | 487 M | 503 M | 102 M | 270 M | 97.7 M | 99.9 M | -211 M | 102 M | 103 M | -224 M | -168 M | - | -185 M | -173 M | -130 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Phreesia, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
So-Young International
SY
|
$ 1.84 | 0.55 % | $ 143 M |  China |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 100.61 | -0.38 % | $ 8.67 B | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.13 | -11.72 % | $ 3.86 M | China |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
American Well Corporation
AMWL
|
$ 10.75 | -0.83 % | $ 173 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 6.05 | -3.51 % | $ 112 M | USA |
 |
Progyny
PGNY
|
$ 31.13 | -1.14 % | $ 2.65 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.07 | -3.15 % | $ 1.09 B | USA |
 |
Schrödinger
SDGR
|
$ 15.14 | -1.37 % | $ 1.11 B | USA |
 |
Omnicell
OMCL
|
$ 35.37 | -4.69 % | $ 1.63 B | USA |
 |
Health Catalyst
HCAT
|
$ 2.09 | 0.48 % | $ 146 M | USA |
 |
HealthStream
HSTM
|
$ 28.04 | -0.57 % | $ 842 M | USA |
 |
Evolent Health
EVH
|
$ 3.09 | -2.83 % | $ 353 M | USA |
 |
Teladoc Health
TDOC
|
$ 6.71 | 2.05 % | $ 1.18 B | USA |
 |
10x Genomics
TXG
|
$ 47.27 | -4.37 % | $ 5.9 B | USA |
 |
Veeva Systems
VEEV
|
$ 203.78 | 1.1 % | $ 33.4 B | USA |